Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023

• DOI: 10.1016/j.athplu.2024.01.004
• Publication Date: 2024-02-17T10:29:47Z
• Authors: N Katsiki; Td Filippatos; C Vlachopoulos; D Panagiotakos; H Milionis; A Tselepis; A Garoufi; L Rallidis; D Richter; T Nomikos; G Kolovou; K Kypreos; C Chrysohoou; K Tziomalos; I Skoumas; I Koutagiar; A Attilakos; M Papagianni; C Boutari; V Kotsis; C Pitsavos; M Elisaf; K Tsioufis; E Liberopoulos
• Keywords: Dyslipidemia; Atherosclerotic cardiovascular disease; Stroke

Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis treatment is paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines Hellenic Atherosclerosis Society focus on assessment risk, laboratory evaluation dyslipidemias, new emerging lipid-lowering drugs, as well lipid disorders in women, elderly patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, non-alcoholic fatty liver disease. Statin intolerance also discussed.